Hugo Calderon

Hugo Calderon has a diverse work experience, primarily focused in the field of biomedical research. Hugo began their career in 2009 as a Salesman at ING. In 2011, they joined the Catalan Institute of Oncology as a Bachelor Thesis Student, where they designed and executed an experimental project to increase the potency of an oncolytic virus. Later that year, they became a Master Thesis Student at the Bellvitge Biomedical Research Institute - IDIBELL, where they conducted research on the delivery of adenovirus 5 to tumors using human erythrocytes. This project resulted in a publication and involved various techniques such as adenovirus infection, purification, and quantitation methods. In 2013, they joined Psioxus Therapeutics as a Research Scientist in Cancer Immunotherapy and Virotherapy. Here, they managed and executed scientific investigations on the oncolytic virus platform, including investigating the mechanism of action for increased potency and pre-clinical evaluation of the virus's synergy with cancer immunotherapy. Hugo also collaborated on other projects, such as characterizing the selectivity of the virus and screening for drugs with modulatory effects.

Hugo Calderon completed their Bachelor's degree in Biology at the Universitat Autònoma de Barcelona from 2006 to 2011. Following this, they pursued a Master's degree in Advanced Immunology at the Universitat de Barcelona, which they completed from 2011 to 2012. From 2013 to 2017, they attended the University of Oxford and obtained their Doctor of Philosophy (Ph.D.) degree in Immunology, with a focus on Virology, Cancer Vaccine, and Oncology.